Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by lscfaon Jun 14, 2021 7:58pm
128 Views
Post# 33386118

RE:RE:RE:We lost 1/2 our share price since launch..

RE:RE:RE:We lost 1/2 our share price since launch..I think the problem is NR's are not stand alone documents. They leave out details that should be reiterated instead of relying on readers being aware of all past disclosures. In the March NR about the R+F launch there were no details on how Sirona was to benefit. Readers probably assumed a standard licensing arrangement was in place. It is only later that readers became aware of the lousy deal Sirona has with R+F that expectations were dampened and the share price retreated.   

forhandlaren wrote: I beg to somewhat differ - the initial decline from 56 cents was because of bozo german investors that expected R+F news at CET time in the morning. Disappointed of not getting any NR they started to sell. 

Nevertheless, the management is not hungry enough to nail deals in time, they like to recognize themselves as victims of the game but could and should step up. Howard wants the partner to be happy and that nice, but I deem that he is way to soft to play the game. The partners find him weak instead of bold and proud. This results in lame deals. I would love to stand corrected!


<< Previous
Bullboard Posts
Next >>